Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 39
Article in Chinese | WPRIM | ID: wpr-928100


This paper discussed the guiding significance of "disease-syndrome-symptom" mode in FU Qing-zhu's Obstetrics and Gynecology(FU Qing-zhu Nyu Ke) for dealing with ovulation disorder infertility caused by hyperprolactinemia(HPRL). FU Qing-zhu's Obstetrics and Gynecology(FU Qing-zhu Nyu Ke) concentrates on the disease entities, main symptoms, pathogenesis, and syndrome differentiation, based on which the prescriptions are prescribed. This reflects the "disease-syndrome-symptom" mode, with the core lying in the "combination of disease with syndrome". The contained Discussion on Menstruation Regulation(Tiao Jing Pian) and Discussion on Getting Pregnant(Zhong Zi Pian) have important reference significance for later doctors in the diagnosis and treatment of inferti-lity, and many prescriptions are still in use due to good effects. It is believed in traditional Chinese medicine(TCM) that HPRL results from kidney deficiency and liver depression, among which kidney deficiency is the main cause. Liver depression accelerates the onset of HPRL, so the kidney-tonifying and liver-soothing herbs were mainly selected. The "disease-syndrome-symptom" mode in FU Qing-zhu's Obstetrics and Gynecology(FU Qing-zhu Nyu Ke) sheds enlightenment on the diagnosis and treatment of ovulation infertility caused by HPRL, in that it is not confined to disease entity and syndrome type. The integration of "disease-syndrome-symptom" highlights the main complaint of patients and emphasizes the main pathogenesis, thus giving full play to the overall advantage of syndrome differentiation. For multiple diseases in FU Qing-zhu's Obstetrics and Gynecology(FU Qing-zhu Nyu Ke) such as infertility due to liver depression, infertility due to obesity, delayed menstruation, and irregular menstruation, although the typical lactation symptom of HPRL is not mentioned, the medication can still be determined according to the chief complaint, syndrome type, and symptoms and signs, making up for the defects of excessive reliance on serum biochemical indicators in modern Chinese medicine. We should learn its diagnosis and treatment thoughts of paying attention to liver, spleen, kidney, and heart, holism, and strengthening body resistance to eliminate pathogenic factors.

Female , Gynecology , Humans , Hyperprolactinemia/drug therapy , Infertility , Obstetrics , Ovulation , Pregnancy
Article in Chinese | WPRIM | ID: wpr-887931


Hyperprolactinemia(HPRL) is one of the diseases leading to anovulatory infertility, which is a refractory gynecological disease and seriously affects female reproductive function. Professor MA Kun has summarized his experience in clinical and scientific studies for many years. And believes that kidney deficiency is the pathogenesis of HPRL and blood stasis is the dominant pathological manifestation of HPRL and can promote the progress of the disease. In view of this, Professor MA Kun took the therapy of kidney-tonifying and blood-activating as the principle for treating anovulatory infertility caused by HPRL, with soothing the liver and promoting Qi as adjuvant therapies. She has also summarized and refined the prescriptions for tonifying kidney and inducing ovulation, which have a remarkable clinical efficacy.

Drugs, Chinese Herbal/therapeutic use , Female , Humans , Hyperprolactinemia/drug therapy , Infertility, Female/etiology , Kidney , Medicine, Chinese Traditional
Medicina (B.Aires) ; 80(6): 670-680, dic. 2020. graf
Article in English | LILACS | ID: biblio-1250290


Abstract Hyperprolactinemia may be associated with psychiatric disorders in the context of two scenarios: antipsychotic-induced hyperprolactinemia and psychiatric disorders arising from the medical treatment of hyperprolactinemia. Both situations are particularly common in psychiatric and endocrine clinical practice, albeit generally underestimated or unrecognized. The aim of this article is to provide tools for the diagnosis and treatment of hyperprolactinemia associated with psychiatric disorders to raise awareness, especially among psychiatrists and endocrinologists, so that these professionals can jointly focus on the appropriate management of this clinical entity.

Resumen La hiperprolactinemia puede asociarse con trastornos psiquiátricos en el contexto de dos escenarios: la hiperprolactinemia inducida por antipsicóticos y trastornos psiquiátricos surgidos por el tratamiento médico de la hiperprolactinemia. Ambas situaciones son particularmente comunes en la práctica clínica psiquiátrica y endocrinológica, aunque generalmente subestimadas o inadvertidas. El objetivo de este artículo es proporcionar herramientas de diagnóstico y tratamiento de la hiperprolactinemia asociada a trastornos psiquiátricos, para concientizar particularmente a psiquiatras y endocrinólogos a enfocar en conjunto el manejo apropiado de esta entidad.

Humans , Antipsychotic Agents/adverse effects , Hyperprolactinemia/diagnosis , Hyperprolactinemia/chemically induced , Hyperprolactinemia/drug therapy , Mental Disorders/etiology , Mental Disorders/drug therapy , Prolactin/metabolism
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 42(1): 33-39, Jan.-Feb. 2020. tab, graf
Article in English | LILACS | ID: biblio-1055365


Objective: To evaluate body dissatisfaction and distorted body self-image in women with prolactinoma. Methods: Body dissatisfaction and distorted body self-image were evaluated in 80 women with prolactinoma. All patients were in menacme, 34% had normal body mass index (BMI), and 66% were overweight. Most patients (56.2%) had normal prolactin (PRL) levels and no hyperprolactinemia symptoms (52.5%). The Body Shape Questionnaire (BSQ) was used to assess the patients' dissatisfaction with and concern about their physical form, and the Stunkard Figure Rating Scale (FRS) was used to assess body dissatisfaction and distorted body self-image. The patients were divided according to PRL level (normal vs. elevated) and the presence or absence of prolactinoma symptoms. Results: The normal and elevated PRL groups had similar incidences of body dissatisfaction and distorted body self-image. However, symptomatic patients reported a higher incidence of dissatisfaction than asymptomatic patients. Distorted body self-image was less common among symptomatic patients. Conclusion: Symptomatic patients showed higher body dissatisfaction, but lower body self-image distortion. The presence of symptoms may have been responsible for increased body awareness. The perception of body shape could have triggered feelings of dissatisfaction compared to an ideal lean body. Therefore, a distorted body self-image might not necessarily result in body dissatisfaction in women with prolactinomas.

Humans , Female , Adult , Young Adult , Pituitary Neoplasms/psychology , Hyperprolactinemia/psychology , Prolactinoma/psychology , Body Dysmorphic Disorders/psychology , Pituitary Neoplasms/blood , Prolactin/blood , Psychiatric Status Rating Scales , Reference Values , Body Image/psychology , Hyperprolactinemia/drug therapy , Hyperprolactinemia/blood , Prolactinoma/blood , Body Mass Index , Surveys and Questionnaires , Statistics, Nonparametric , Dopamine Agonists/therapeutic use , Middle Aged
Rev. chil. endocrinol. diabetes ; 13(2): 61-63, 2020. ilus
Article in Spanish | LILACS | ID: biblio-1095286


El quiste de la bolsa de Rathke es una lesión epitelial benigna de la región selar, formada a partir de remanentes embrionarios. La mayoría de los casos son asintomáticos, aunque pudiera presentarse con cefalea, disfunción hipofisaria y trastornos visuales, muy infrecuentemente como apoplejía hipofisaria. Se presenta el caso de una paciente que, habiendo presentado amenorrea primaria, se le realiza el diagnóstico de quiste de la bolsa de Rathke con hiperprolactinemia, logrando menarquia luego del tratamiento con cabergolina.

Rathke's cyst is a benign epithelial lesion of the sellar region, formed from embryonic remnants. Most cases are asymptomatic although it could present with headache, pituitary dysfunction and visual disorders, very infrequently as pituitary stroke. We present the case of a patient who, having presented primary amenorrhea, is diagnosed with Rathke's cyst with hyperprolactinemia, achieving menarche after treatment with cabergoline.

Humans , Female , Adolescent , Hyperprolactinemia/complications , Central Nervous System Cysts/complications , Amenorrhea/etiology , Prolactin/therapeutic use , Hyperprolactinemia/diagnosis , Hyperprolactinemia/drug therapy , Magnetic Resonance Imaging , Tomography, X-Ray Computed , Central Nervous System Cysts/diagnosis , Central Nervous System Cysts/drug therapy , Cabergoline/therapeutic use
Rev. cuba. endocrinol ; 28(3): 1-13, set.-dic. 2017. ilus
Article in Spanish | LILACS | ID: biblio-901028


Antecedentes: la apoplejía hipofisaria es un síndrome clínico agudo, potencialmente fatal, que acontece como complicación de un adenoma hipofisario; presenta una complejidad diagnóstica, y puede imitar numerosos procesos intracraneales. Objetivo: realizar la revisión bibliográfica del tema, y describir dos casos clínicos, dada la poca frecuencia de presentación de la enfermedad y su complejidad diagnóstica. Desarrollo: caso 1, paciente masculino, de 52 años con antecedentes patológicos de hipertensión arterial y macroadenoma hipofisario no funcionante. Durante su seguimiento por Neurocirugía se detectó hiperprolactinemia, por lo que se inició tratamiento con bromocriptina a dosis progresiva, lo cual desencadenó cuadro agudo no definido. Tres meses después presentó nuevo cuadro agudo, que se diagnosticó como apoplejía hipofisaria; caso 2, paciente masculino, de 49 años, con antecedente de hipertensión arterial con tratamiento irregular. Fue ingresado en servicio de terapia intermedia con diagnóstico presuntivo de meningoencefalitis, y por estudios complementarios se llega al diagnóstico de apoplejía hipofisaria. Ambos casos llevaron tratamiento quirúrgico, con evolución favorable. Conclusiones: la apoplejía hipofisaria es una enfermedad que se presenta con poca frecuencia, por lo tanto, es importante la sospecha diagnóstica para una temprana identificación y tratamiento de la enfermedad(AU)

Background: pituitary apoplexy is an acute clinical syndrome, potentially fatal, that occurs as a complication of a pituitary adenoma. It presents a diagnostic complexity, and it can mimic numerous intracranial processes. Objective: to carry out the bibliographic review of the subject, and to describe two clinical cases given the infrequency of presentation of the disease and its diagnostic complexity. Development: case 1, male patient, 52 years old with pathological history of arterial hypertension and non-functioning pituitary macroadenoma. During follow-up by Neurosurgery, hyperprolactinemia was detected, so treatment with bromocriptine was started with a progressive dose, which triggered undefined acute symptoms. Three months later he presented new acute symptoms, which was diagnosed as pituitary apoplexy. Case 2, male patient, 49 years old, with a history of arterial hypertension under irregular treatment. He was admitted in the intermediate therapy service with a presumptive diagnosis of meningoencephalitis, and by complementary studies the diagnosis of pituitary apoplexy was reached. Both cases led to surgical treatment, with favorable evolution. Conclusions: pituitary apoplexy is a disease that occurs infrequently, therefore, diagnostic suspicion is important for early identification and treatment of the disease(AU)

Humans , Male , Middle Aged , Bibliographies as Topic , Pituitary Apoplexy/surgery , Pituitary Apoplexy/diagnosis , Hyperprolactinemia/drug therapy , Review Literature as Topic
Rev. chil. endocrinol. diabetes ; 8(1): 25-31, ene.2015. tab
Article in Spanish | LILACS | ID: lil-789320


Hyperprolactinemic males usually have a hypoactive libido and less commonly, erectile dysfunction and disturbances of orgasm and ejaculation. Hyperprolactinemia alters the balance between neurotransmitters, neuropeptides and hormones involved in libido and erection, affecting dopaminergic tone. An imbalance between dopamine, that stimulates sexual function and serotonin that inhibits it, is generated. In the central nervous system, hyperprolactinemia inhibits centers controlling sexual desire and erection. At the neuroendocrine level, it decreases GnRH, LH and testosterone pulses, resulting in a hypogonadotrophic hypogonadism. Erection is also inhibited peripheral actions of low testosterone and high prolactin levels. There is a disturbance of penile smooth muscle relaxation and of the parasympathetic sacrum-penis reflex arch. In experimental animals, acute hyperprolactinemia hampers the central erection mechanism whereas in chronic conditions, peripheral disturbances also occur. Even correcting low testosterone levels, the adverse effects of hyperprolactinemia on sexual function persist. The use of dopaminergic agonists may achieve normal prolactin and testosterone levels resulting in normal sexual function. Chronic hyperprolactinemia results in progressive deterioration of sexual function and a higher hypothalamic damage that does not respond to clomiphene. In this situation and in the presence of sellar tumors that destroy gonadotrophic cells, there is indication of androgenic replacement maintaining the use of dopaminergic agonists...

Humans , Male , Adult , Sexual Dysfunction, Physiological/etiology , Hyperprolactinemia/complications , Hyperprolactinemia/diagnosis , Hyperprolactinemia/drug therapy , Dopamine Agonists/therapeutic use , Clomiphene/therapeutic use , Hyperprolactinemia/physiopathology
Medical Sciences Journal of Islamic Azad University. 2010; 20 (3): 163-169
in English, Persian | IMEMR | ID: emr-117958


Cabergoline is a strong dopaminergic agonist that is derived from Ergot fungus. Although, this drug can be so important in treating many disorders such as hyperprolactinemia, but its side effects are considerable on the endocrinal axis. The purpose of this study was to determine effects of cabergoline on serum levels of TSH, T[4] and T[3] hormones in adult male rats. In this experimental study, 40 adult male wistar rats were used in five groups of eight. The drug was subcutaneously injected for a period of 14 days. The experimental groups received 0.1, 0.5 and 1 mg/kg, respectively. The control group received no drug. The sham group received only distilled water. At the end of 14[th] day, blood samples were taken and the concentration of TSH, T[4] and T[3] were measured by RIA. The results were analyzed by ANOVA and TUKEY test between the control and experimental group. Serum levels of TSH and T4 hormones in the experimental groups with doses of 0.1, 0.5 and 1 mg/kg showed statistically significant decrease compared with control group [p<0.05]. Concentration of T[3] hormone showed significant increase in the experimental group with 0.1 mg/kg in comparison with control group [p<0.05]. Cabergoline probably decreases the release of TSH and T[4] by stimulating the D[2]-dopaminergic receptor existing in thyrotrophic cells. According to the increase of T[3] concentration with low dose of drug, cabergoline may have different physiological effects in different amounts, and alter the function of pituitary -thyroid axis

Animals, Laboratory , Male , Hyperprolactinemia/drug therapy , Treatment Outcome , Thyroid Hormones/metabolism , Rats , Dose-Response Relationship, Drug
Rev. cuba. endocrinol ; 20(3)sept.-dic. 2009.
Article in Spanish | LILACS, CUMED | ID: lil-575699


La cabergolina y la bromocriptina son fármacos agonistas dopaminérgicos utilizados para tratar la hiperprolactinemia, así como la enfermedad de Parkinson. Entre sus efectos adversos considerados como muy raros se ha descrito la capacidad de inducir cambios fibróticos en el aparato valvular cardiaco, inicialmente descritos en pacientes con enfermedad de Parkinson, en quienes se emplean dosis superiores a las que de manera habitual se emplean en el tratamiento de la hiperprolactinemia. Varios estudios han señalado la evidencia de estos hechos y de los posibles mecanismos por los cuales la afectación valvular ocurre. Existen hasta el momento pocas investigaciones sobre el asunto en pacientes con hiperprolactinemia, pero la mayoría de ellos indican que su empleo en este tipo de pacientes no produce afectación valvular clínicamente relevante, hecho que pudiera estar en relación con las dosis empleadas (como promedio 10 veces inferiores a las usadas en la enfermedad de Parkinson); sin embargo, se han detectado algunas anomalías subclínicas en el aparato valvular. Dado lo novedoso del tema y la poca evidencia de estos hechos en pacientes tratadas por hiperprolactinemia se ofreció una amplia revisión sobre el tema(AU)

Cabergoline and bromocriptine are dopaminergic agonists drugs used in hyperprolactinemia treatment, as well as in patients with Parkinson's disease. Among its adverse effects considered as very inusual is included the ability to induce fibrotic changes in cardiac valvular tract first described in patients with Parkinson disease using doses higher than those usually used in hyperprolactinemia treatment. Some studies have mentioned the evidence on these facts and of the possible mechanisms causing the valvular affection. Until now, there are not much researches on this subject in patients with hyperprolactinemia, but most indicated that its use in this kind of patient can not to produce a clinically relevant valvular afection, fact tha may to be related to the dose used (on average 10 times lower than those used in Parkinson's disease); however, some subclinical anomalies have been detected in valvular tract. Due to this novel subject and the scarce evident of these facts in patients treated by hyperprolactinemia, we offered an review of the subject(AU)

Humans , Hyperprolactinemia/drug therapy , Dopamine Agonists/adverse effects , Dopamine Agonists/therapeutic use , Heart Valve Diseases/chemically induced
Cir. & cir ; 77(3): 173-177, mayo-jun. 2009. tab, graf
Article in Spanish | LILACS | ID: lil-566503


Introducción: La terapia de elección de los prolactinomas son los agonistas dopaminérgicos, cuyo principal exponente es la bromocriptina, sin embargo, hay pacientes que no responden o presentan severos efectos secundarios (resistentes o intolerantes a bromocriptina, respectivamente). El objetivo en este estudio fue valorar la respuesta al uso de cabergolina en pacientes con prolactinomas, intolerantes o resistentes a bromocriptina Material y métodos: Se estudiaron 27 pacientes (25 mujeres y dos varones) en quienes se realizó determinación basal de prolactina y cada mes hasta completar tres meses, registrando los datos asociados a hiperprolactinemia y los efectos secundarios. La dosis inicial fue de 0.25 mg los lunes y jueves durante la primera semana, y 0.5 mg a partir de la segunda. El análisis estadístico incluyó la prueba de Shapiro-Wilk, Kruskal-Wallis y Anova. Resultados: 22 pacientes presentaron microadenomas y cinco macroadenomas. En los intolerantes (n = 11) el valor inicial de prolactina de 61.45 ± 19.82 disminuyó al tercer mes a 4.94 ± 1.79 (p < 0.024). En los resistentes (n = 16), el valor basal fue 119.53 ± 11.52; 15 pacientes redujeron significativamente a 12.95 ± 3.66 (p < 0.005) al tercer mes de tratamiento. En ambos, los signos atribuibles a la hiperprolactinemia mejoraron significativamente, con poca incidencia de efectos secundarios. Conclusiones: La cabergolina es útil en la mayoría de los pacientes considerados intolerantes o resistentes a la bromocriptina.

BACKGROUND: Dopaminergic agonists are the treatment of choice for prolactinomas with bromocriptine (BCE) being the primary agent used. There is a group of patients who are not responders to such therapy or have severe side effects (resistant or intolerant to BCE, respectively). We undertook this study to evaluate the response to the administration of cabergoline (CBG) in patients intolerant or resistant to BCE. METHODS: Twenty seven patients (25 females and 2 males) were recruited with prolactin-pituitary tumors, obtaining basal serum prolactin (PRL) samples and again each month up to 3 months. We recorded signs associated with hyperprolactinemia and secondary effects of CBG. The initial dose was 0.25 mg twice weekly during the first week, with an increase to 0.5 mg twice weekly from the second week until the conclusion of the study. Statistical analysis included Shapiro-Wilk, Kruskal-Wallis and ANOVA tests. RESULTS: Twenty two patients had microadenomas and five had macroadenomas. In the intolerant group (n= 11), the initial PRL value (61.45 +/- 19.82) decreased by the third month to 4.94 +/- 1.79 (p<0.024). In the resistant group (n= 16), basal PRL values were 119.53 +/- 11.52. In 15 of these patients, the PRL value significantly decreased to 12.95 +/- 3.66 ng/ml (p<0.005) by the third month of treatment. In both groups the signs related to hyperprolactinemia significantly improved, with a low incidence of secondary effects due to CBG. CONCLUSIONS: CBG is useful in most patients considered as intolerant or resistant to BCE.

Humans , Male , Female , Adult , Dopamine Agonists/therapeutic use , Ergolines/therapeutic use , Hyperprolactinemia/drug therapy , Pituitary Neoplasms/drug therapy , Prolactinoma/drug therapy , Bromocriptine/adverse effects , Bromocriptine/therapeutic use , Drug Tolerance , Hyperprolactinemia/etiology , Pituitary Neoplasms/complications , Prolactinoma/complications
Article in Spanish | LILACS | ID: lil-617561


La hiperprolactinemia constituye la altelaración endocrina más común del eje hipotálamo-hipofisario, aunque su prevalencia en la población infantojuvenil no está aún claramente definida. Además de la Prolactina (PRL) nativa (23Kda), se han descripto numerosas variantes moleculares, algunas de ellas con menor o ausente actividad biológica. Todo proceso que interrumpa la secreción de dopamina, interfiera con su liberación hacia los vasos portales hipofisarios o bloquee los receptores dopaminérgicos de las células lactotróficas, puede causar hiperprolactinemia. Si bien la patología tumoral constituye el diagnóstico de mayor relevancia, los prolactinomas son poco frecuentes en nios y adolescentes, aunque tienen en general una particular presentación clínica: de acuerdo con nuestra experiencia, el retraso puberal puede observarse en aproximadamente el 50% de las pacientes de sexo femenino. En pacientes con hiperprolactinemia asintomática debe evaluarse la presencia de proporciones alteradas de isoformas de PRL. La cromatografía en columna con sephadex G100, la precipitación con suspención de proteína A o con PEG y la ultracentrifugación constituyen los métodos más frecuentemente empleados para la detección de las distintas isoformas de PRL. En nuestra experiencia la B PRL constituyó el 6,6 - 32,6% de la PRL total y la BB PRL contituyó el 40 y el 72% de çesta en este gruo de pacientes. En cuanto al tratamiento por su efectividad y tolerancia, los agonistas dopaminérgicos constituyen la terapia inicial de elección en pacientes en edad pediátrica. La bromocriptina y la cabergolina han sido empleadas y con resultados similares a los de los pacientes adultos.

Humans , Adolescent , Child , Dopamine Agonists/administration & dosage , Hyperprolactinemia/diagnosis , Hyperprolactinemia/etiology , Hyperprolactinemia/drug therapy , Prolactin/physiology , Bromocriptine/administration & dosage , Magnetic Resonance Imaging , Pituitary Neoplasms/diagnosis , Pergolide/administration & dosage
Indian J Pediatr ; 2006 May; 73(5): 435-6
Article in English | IMSEAR | ID: sea-84046


Prolactinomas, the most common pituitary adenomas, are important causes of infertility. Bromocriptine remains the treatment of choice for managing hyperprolactinemia in most of these cases. Breastfeeding in mothers receiving bromocriptine is often doubtful and matter of concern for most people. Here we report a case, where by timely intervention and skilled counseling, exclusive breastfeeding could be established in a mother receiving bromocriptine for the treatment of hyperprolactinemia.

Adult , Breast Feeding , Bromocriptine/therapeutic use , Counseling , Female , Hormone Antagonists/therapeutic use , Humans , Hyperprolactinemia/drug therapy , Infant Nutritional Physiological Phenomena , Infant, Newborn , Pituitary Neoplasms/complications , Prolactinoma/complications
Medical Journal of Reproduction and Infertility. 2002; 3 (12): 36-41
in English, Persian | IMEMR | ID: emr-60153


Hyperprolactinemia is the most common cause of amenorrhea and infertility. Oral bromocriptine is the drug of choice for the treatment of hyperprolactinemia. Due to complications of its oral use, vaginal bromocriptine has been introduced as an effective and safe method. There is limited information regarding possible side effects of vaginal bromocriptine on motile sperm count in PCT results. Thus, in this clinical cross-sectional study, we sought to determine possible effects of vaginal bromocriptine on motile sperm count in PCT after resumption of ovulatory cycle in outpatients in reproductive age with hyperprolactinemia and complaints such as galactorrhea, menstrual irregularity and infertility. After exclusion of all confounding factors, the patients were divided in two groups. The study group [n=11] was treated with vaginal bromocriptine 2.5mg daily, and the control group [n=15] was treated with oral bromocriptine 2.5-5mg daily. Treatment duration needed for marked reduction in prolactine and also initiation of menses and ovulatory cycles were evaluated in both groups. After restoration of ovulation, PCT was done on 13-14th day of cycle in the presence of good cervical mucus, 8-12 hours after coitus. The numbers of motile sperm count atozoa/HPF in both groups were recorded and statistically compared with Mann Whitney U test. Treatment durations needed for initiation of ovulatory cycles in study group and the control group were 4-8 [mean5.5] weeks and 4-7 [mean 5.8] weeks, respectively with no statistical difference [p>0.05]. PCT results showed 11-20 [mean15.3] motile sperm/HPF with progressive forward movement in study group, who were treated with vaginal bromocriptine. By using oral bromocriptine, PCT showed 10-23 [mean 14.4] motile sperm/HPF with progressive forward movement in the control group. There were no statistical difference in PCT results between these two groups [p>0.05]. These results suggests the hypothesis, that vaginal bromocriptine has no adverse effects on motile sperm count in PCT, and vaginal bromocriptine can be used safely without possible adverse effect on sperm function in women with hyperprolactinemia and infertility. However, larger studies with more cases are necessary to confirm this hypothesis and to determine if vaginal bromocriptine has any effect on fertility in both groups

Humans , Female , Bromocriptine/administration & dosage , Hyperprolactinemia/drug therapy , Bromocriptine , Infertility, Female/etiology , Infertility, Female/drug therapy , Cross-Sectional Studies , Administration, Intravaginal , Statistics, Nonparametric , Administration, Oral , Sperm Motility/drug effects
Medicina (B.Aires) ; 61(3): 275--278, 2001. tab
Article in Spanish | LILACS | ID: lil-290121


En su gran mayoría los enfermos portadores de hipotiroidismo subclínico (HScl) son asintomáticos. Sin embargo, hemos tenido la oportunidad de entrevistar a enfermas con dicha patología, con manifestaciones clínicas y bioquímicas del sector lactotrófico adenohipofisario. Para explicar nuestros hallazgos seleccionamos a cinco mujeres con hipotiroidismo estadio I y seis en estadio II, comprobando que a medida que se profundiza la enfermedad, más se altera el eje gonadotrófico. Al resultar tan escasa la información bibliográfica diseñamos una sistemática de estudio de los diversos ejes neuroendocrinos en esta afección, con el fin de excluir otra noxa asociada.

Humans , Adolescent , Adult , Female , Hyperprolactinemia/etiology , Hypothyroidism/complications , Galactorrhea/physiopathology , Hormone Replacement Therapy , Hyperprolactinemia/drug therapy , Hypothyroidism/drug therapy , Hypothyroidism/pathology , Menstruation Disturbances/etiology , Prolactin/blood , Thyroxine/therapeutic use
Arq. neuropsiquiatr ; 58(3A): 671-6, set. 2000. tab
Article in Portuguese | LILACS | ID: lil-269615


Sintomas psicológicos, especialmente ansiedade e depressao, têm sido associados à hiperprolactinemia. Para avaliar a presença desses sintomas, foram submetidos à entrevista através do Composed International Diagnostic Interview, seguido pela escala de Hamilton para depressao, 32 pacientes (5 homens e 27 mulheres) com hiperprolactinemia de várias etiologias e 16 normoprolactinêmicos. A prolactina sérica na época da avaliaçao variou de 28 a 180 ng/mL, sendo que 11 dos pacientes usavam bromocriptina. Detectou-se presença atual de distúrbios de ansiedade em 18 pacientes (56,2 por cento) e 5 controles (31,2 por cento), depressao em 10 pacientes (31,2 por cento) e 2 controles (12,5 por cento), distmia em duas pacientes e outros diagnósticos psiquiátricos em 6 pacientes (18,7 por cento). Os escores da depressao variaram entre 16 e 31 nos pacientes e foram 12 e 16 nos controles. A frequência de sintomas psiquiátricos como um todo, foi significativamente maior nos hiperprolactinêmicos (teste do qui-quadrado), mas a diferença nao foi significativa na análise isolada de ansiedade ou depressao. A hiperprolactinemia representa um fator de risco de 3,57 para depressao, 3,32 para ansiedade e 3,84 para outros sintomas psiquiátricos. Nao houve diferença significativa na frequência de sintomas psiquiátricos entre portadores ou nao de adenomas hipofisários e usuários ou nao de bromocriptina. Nao houve correlaçao (r= 0,07) entre a prolactina e a frequência de sintomas psiquiátricos. Conclui-se pela necessidade de atentar para a concomitância de hiperprolactinemia e distúrbios psiquiátricos, cujo reconhecimento permitirá abordagem terapêutica específica

Humans , Male , Female , Hyperprolactinemia/psychology , Mental Disorders/etiology , Anxiety Disorders/etiology , Bromocriptine/therapeutic use , Case-Control Studies , Chi-Square Distribution , Depressive Disorder/etiology , Dopamine Agonists/therapeutic use , Hyperprolactinemia/complications , Hyperprolactinemia/drug therapy , Interview, Psychological , Psychiatric Status Rating Scales , Risk Factors
JCPSP-Journal of the College of Physicians and Surgeons Pakistan. 1999; 9 (1): 28-31
in English | IMEMR | ID: emr-50899


A prospective observational study was designed to determine the response to Bromocriptine [Parlodel] therapy in terms of occurrence of pregnancy and its outcome in women who had infertility associated with galactorrhea and hyperprolactinaemia. A total of 29 infertile women found to have galactorrhea and hyperprolactinaemia. Out of them 40% had primary infertility and 60% were of secondary infertility. About 27% patients had associated menstrual problems. After excluding or treating other causes of infertility Bromocriptine therapy was instituted with the minimum dose and slowly building up the requried dosage. In 73% [21/29] patients Bromocriptine was prescribed in a dosage of 5 mg per day and 7.5 mg was given to the rest of the cases. Tolerance to Bromocriptine was quite remarkable. Pregnancy was achieved in 48% [11/23] cases, in 36% cases of primary infertility and 64% of secondary infertility. About 82% [9/11] conceptions occurred within 2 to 6 months of therapy and of the 11 pregnancies 9 ended as successful term deliveries. Clomiphene citrate was given to 27% [3/11] patients due to ovulatory dysfunctions

Humans , Female , Hyperprolactinemia/drug therapy , Bromocriptine
JCPSP-Journal of the College of Physicians and Surgeons Pakistan. 1999; 9 (1): 32-34
in English | IMEMR | ID: emr-50900


A total of 70 patients with hyperprolactinaemic infertility were studied over a period of one year. Our goal was to compare two treatment regimens: bromocriptine plus placebo and bromocriptine plus clomiphene citrate in management of these patients. A double-blinded randomised, placebo-controlled trial was carried out. Ovulation/conception was achieved in a shorter time with greater safety and success rate in patients receiving combined therapy as compared to patients on bromocriptine alone

Humans , Female , Hyperprolactinemia/drug therapy , Bromocriptine
Article in Spanish | LILACS | ID: lil-255349


Se presentan cinco pacientes cuyo motivo fundamental de consulta fue la amenorrea primaria, una de ellas, la más joven, con ausencia de desarrollo sexual, las cuatro restantes con desarrollo normal de caracteres sexuales secundarios. En todas, las causas determinante del cuadro clínico fue la hiperprolactemia. En tres de nuestras pacientes se demostró, por tomografía axial computarizada (TAC), la existencia de microadenoma hipofisiario como causa de la hiperprolactinemia y en las dos restantes no se comprobó la presencia de tumor hipofisiario, en una de ellas se encontró signos imagenológicos compatibles de silla turca vacía. Se hace énfasis en la importancia de descartar la hiperprolactinemia en toda paciente con amenorrea primaria aún sin otro síntomas clínico acompañantes, lo que permitiría un diagnóstico precoz y de fácil reversibilidad

Humans , Female , Adolescent , Adult , Amenorrhea/etiology , Hyperprolactinemia/complications , Amenorrhea/diagnosis , Bromocriptine/therapeutic use , Hyperprolactinemia/drug therapy , Hyperprolactinemia/etiology , Pituitary Neoplasms/complications , Prolactin/metabolism , Tomography, X-Ray Computed